|
 |
|
      |
|
| » What We Do
» Who We Are - Board of Directors - Scientific Council - National Leadership Council - Leadership Awards - Staff - Contact Us » History & Accomplishments » Financial Information 
|
 Biography   Alexander H. Glassman, M.D. Chief of Clinical Psychopharmacology New York State Psychiatric Institute Professor of Psychiatry Columbia University College of Physicians and Surgeons Studies of depression and antidepressant drugs conducted by Dr. Glassman and his group have contributed to the standard of care for depressed patients. His research showed that differences among patients in metabolizing the tricyclic antidepressants influenced clinical outcome, and that delusional unipolar depression responded poorly to antidepressant drugs alone. His work clarified the safety of selective serotonin reuptake inhibitor antidepressant (SSRI) treatment following a heart attack, and he has contributed to establishing the relationship between depression and cardiovascular mortality. In a related area, Dr. Glassman demonstrated a strong association between major depression and cigarette smoking — a history of depression greatly reduces the chances a smoker will stop smoking, and that when such an individual does stop, it raises significant risk of serious depression. This work led to the use of the antidepressant bupropion for smoking cessation. Dr. Glassman joined NARSAD’s Scientific Council in 2000 and received NARSAD Distinguished Investigator Awards in 1990 and 2005. |
Latest News from NARSAD
Upcoming NARSAD Events
Infoline
|
